If you are on compounded tirzepatide, what patients need to know has changed since you started. You may have begun in 2024, when Zepbound and Mounjaro were hard to find and a clinic online offered a vial the same week. It worked, perhaps very well, and then the dose kept rising, the progress slowed, and the questions you asked were answered with the next dose rather than a reason.
This piece sets out the record for compounded tirzepatide as it stands in October 2026, what it means for you if you are on it now, and how a move to the branded medicine works. GoodLife Health is a clinician-led membership that prescribes branded, FDA-approved medication only and never compounded GLP-1. We have a view, and we will show you the facts underneath it.
- Tirzepatide is the active ingredient in Zepbound, approved for chronic weight management, and Mounjaro, approved for type 2 diabetes; compounded versions of it are not FDA-approved.
- The FDA declared the tirzepatide shortage resolved in December 2024, and the grace periods for compounders closed on February 18, 2025 for 503A pharmacies and on March 19, 2025 for 503B facilities.
- The FDA does not review compounded drugs for safety, effectiveness or quality, and it has recorded dosing errors with compounded GLP-1 products.
- Through LillyDirect, Zepbound vials were $299 to $449 a month depending on dose as of September 2026, sold to self-pay patients at a published price.
- A move from compounded to branded starts with labs and a clinician's decision, never a guessed conversion.
Why so many people started on compounded tirzepatide
Tirzepatide acts on two hormone pathways, GIP and GLP-1, and its published trials reported large average weight loss. Demand outran supply. Tirzepatide went onto the FDA's drug shortage list, and while it was there, federal law allowed two kinds of pharmacy to compound copies: state-licensed 503A pharmacies, which compound for individual patients, and 503B outsourcing facilities, which can produce in larger volume.
For many people, a compounded vial was the only way to start. That was a reasonable decision at the time, and nothing in this piece is meant to suggest otherwise.
What changed, with dates
The FDA declared the tirzepatide shortage resolved in December 2024. It then gave compounders a window to stop producing shortage-era copies: the grace period ended on February 18, 2025 for 503A pharmacies and on March 19, 2025 for 503B outsourcing facilities. The FDA's page on medications containing semaglutide and tirzepatide records the change.
What remains is narrow. A 503A pharmacy may still compound tirzepatide for an individual patient when a prescriber documents a clinical reason the approved product cannot meet. That is a different thing from a clinic selling compounded tirzepatide to every new patient as a routine substitute for Zepbound, and the clinic and pharmacy doing the second have taken a position on your behalf that the law no longer supports in general.
The obligations fall on them, not on you. What falls on you is the practical question of what you are injecting and who is watching what it does.
What is known about compounded tirzepatide
The FDA's page on unapproved GLP-1 drugs used for weight loss states that compounded drugs are not FDA-approved and that the agency does not review them for safety, effectiveness or quality before they are marketed. It records adverse event reports involving compounded GLP-1 products, including dosing errors, some from patients drawing their own doses in units from multi-dose vials, and it notes compounded versions made with added ingredients.
The large trials that made tirzepatide famous were run on the approved medicine. No trial has been run on a particular compounded product, so no one can tell you that a given vial performs the way Zepbound did in those trials. We do not say compounded tirzepatide is dangerous in itself. We say its safety and its equivalence are not established, and that a clinician who prescribes it is putting a licence behind a product whose contents rest on one pharmacy's practices.
There is no reliable shortcut for converting a compounded tirzepatide dose in units into a Zepbound or Mounjaro dose in milligrams. Keep taking your current dose until a clinician has reviewed your history and labs and set the branded starting dose with you.


Zepbound or Mounjaro, and what each one is for
Zepbound and Mounjaro contain the same molecule. Zepbound is approved for chronic weight management; Mounjaro is approved for type 2 diabetes. Which one a clinician prescribes depends on your diagnosis, not on which name is easier to find, and whether a plan covers either is a matter between you, your plan and your pharmacy. Prior authorization is the pharmacy's process, and we never promise coverage.
For self-pay patients, Lilly now sells Zepbound vials directly. Through LillyDirect, Zepbound vials were $299 to $449 a month depending on dose as of September 2026, according to Lilly's Zepbound savings page. Branded still costs more than the cheapest compounded vial, and we will not argue otherwise. What the published price gives you is the approved medicine, a fixed dose, and a price you can see before you buy.
What the dose was never going to fix
A plateau on tirzepatide at a high dose is common, and it is rarely a sign that the medicine needs to be pushed harder. More often something underneath has not been looked at: insulin resistance that has not been measured, a thyroid that has drifted, polycystic ovary syndrome, a medication that works against the GLP-1, or a loss of muscle nobody has measured.
None of that shows up in a dose schedule. It shows up in labs and in a clinician's attention. Our clinicians work to a rule our clinical lead puts in one sentence: "I don't automatically increase a GLP-1 every month because the dosing schedule says that another dose exists." The first response to a stall is a panel, not a price increase.
Side effects that deserve a clinician's attention
Most of what people feel on tirzepatide is expected and manageable: nausea, reflux, constipation or loose stools, a smaller appetite, and tiredness in the first weeks after a dose change. These are reasons to tell your care team, not reasons to tough it out alone. A clinician can adjust timing, food and fluids, the pace of any dose change, and the medicines you take alongside it.
Some symptoms need a faster answer. Severe abdominal pain that does not settle, especially pain that spreads to the back, persistent vomiting, signs of dehydration, or pain under the right ribs after meals should be seen the same day. The approved labels for tirzepatide carry warnings about the pancreas, the gallbladder and the kidneys, and those warnings exist because these problems, while uncommon, are the ones that matter most when they happen. If you take insulin or a sulfonylurea for diabetes, low blood sugar is a risk a clinician should plan for before your first dose.
Then there are the slower changes nobody mentions on a dose schedule. Hair shedding after rapid weight loss, a loss of strength that suggests muscle is going with the fat, and fatigue that does not lift are signals worth working up. A metabolic panel, a blood count and thyroid function are part of how a clinician tells an expected adjustment from a problem.
On a compounded product, two further questions sit behind every side effect: whether the dose you drew was the dose you meant, and whether the vial contains only what its label says. On the branded medicine those questions are answered before the pen reaches you, which leaves the clinician free to look at you.
How a move to branded works with GoodLife Health
Bring your history. The product and concentration on your label, your dose in units, how long you have been at it, and what has happened to your weight, appetite and side effects.
Labs first. The membership includes four cardiometabolic lab panels a year: fasting insulin, A1C, a lipid panel with ApoB and Lp(a), hs-CRP, thyroid function, a metabolic panel and a blood count, with every result in your hands.
The clinician decides with you. Zepbound or Mounjaro, or another approved medicine if one fits better, at a starting dose set from your history and results. There is no forced restart and no automatic escalation.
Your pharmacy fills it. The prescription goes to the pharmacy you choose, including LillyDirect, at that pharmacy's own price. We set nothing on the medication, see nothing on it and take nothing from it.
Where tirzepatide care is going
The record since December 2024 points in one direction. The shortage is over, the manufacturer sells the branded medicine to self-pay patients at a published price, and the reason the compounded market grew has largely gone. Dual-pathway medicines like tirzepatide changed what weight care can achieve. What they did not change is that a medicine without a diagnosis is a guess at scale.
We think the next phase of this care puts the diagnosis first and the medicine second: the markers measured every quarter, a clinician who stays, and the branded medicine bought at the pharmacy's price. GoodLife Health is built for that.
What it costs, what it buys, and what it does not
The GoodLife Health membership is $299 a month, month to month. $598 is held on your card at sign-up, charged only once you are accepted, and covers the first two months. If a clinician cannot accept you into care, the $598 hold is released and you are never charged; once you are accepted, the first two months are non-refundable. Medication billed by a pharmacy follows that pharmacy's own return and refund policy. The fee is the same whatever the medication and whatever the dose.
It buys the quarterly panel, a clinician licensed in your state who stays, messaging and video visits, and branded medication prescribed when indicated to your pharmacy at its price. It returns the reason your progress changed. It does not replace your health insurance, and it does not guarantee weight loss, coverage of a medication or acceptance into care.
Who this is not for
If you want to stay on compounded tirzepatide at the lowest possible price, GoodLife Health is not for you; we do not compete with the $99-a-month compounded app and will not prescribe compounded GLP-1. It is also not for someone who wants a prescription without labs, for anyone under 18, pregnant or planning a pregnancy on a GLP-1, for someone who needs urgent or full-scope primary care, or for anyone outside the United States. If $299 a month would be a strain, choose care you can sustain.
A medicine without a diagnosis is a guess at scale.
Frequently Asked Questions
Is compounded tirzepatide still available legally?
Only narrowly. The FDA declared the tirzepatide shortage resolved in December 2024, and the grace periods closed on February 18, 2025 for 503A pharmacies and March 19, 2025 for 503B facilities. Compounding for an individual patient with a documented clinical reason remains legal.
Is compounded tirzepatide the same as Zepbound?
It claims the same active ingredient, but it is not FDA-approved, it was not the product tested in the published trials, and the FDA does not review it before sale.
How much does branded Zepbound cost without insurance?
Through LillyDirect, Zepbound vials were $299 to $449 a month depending on dose as of September 2026. That is paid to the pharmacy, separately from any clinician's fee.
Can GoodLife Health move me from compounded tirzepatide to Zepbound or Mounjaro?
If you are accepted into care, yes, when it is clinically indicated. A clinician reviews your history and labs first and sets the branded starting dose with you.
Related Reading
- Compounded GLP-1 vs Brand Name: What Patients Need to Know
- The True Monthly Cost of GLP-1 Telehealth
- How GLP-1 Telehealth Companies Make Money: A Plain-Language Whitepaper
- Aligned Medicine: How Zero-Markup Healthcare Actually Works
References
- FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (U.S. Food and Drug Administration). 2025. www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- FDA: Medications Containing Semaglutide and Tirzepatide, Safety Information and Compounding. 2025. www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss
- Zepbound Self Pay Journey Program: LillyDirect vial pricing (Eli Lilly). 2026. zepbound.lilly.com/savings